Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
Rhea-AI Summary
Atossa Therapeutics (NASDAQ:ATOS), a clinical-stage biopharmaceutical company focused on breast cancer treatment and prevention, has appointed CORE IR as its strategic investor relations and communications partner. The collaboration aims to enhance investor awareness and strengthen shareholder engagement through comprehensive IR services.
Under the agreement, CORE IR will provide strategic messaging, non-deal roadshow support, investor targeting and outreach, and communication program support. The partnership reflects Atossa's commitment to improving market visibility and communicating its progress to both institutional and retail investors.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ATOS gained 0.99%, reflecting a mild positive market reaction. This price movement added approximately $1M to the company's valuation, bringing the market cap to $114M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Engagement to enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiences
SEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory firm, to support the Company’s ongoing investor relations and communications initiatives. CORE IR specializes in emerging and established growth company strategies that enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiences.
Dr. Steven Quay, Chairman and CEO of Atossa, commented, “Our collaboration with CORE IR represents our continued commitment to drive value for our stakeholders and with the investment community. We are executing to plan and excited to communicate our progress with increasing market visibility. We believe CORE IR’s stewardship will help us better articulate our value proposition to existing and prospective shareholders.”
Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, non-deal roadshow support, investor targeting and outreach, and support for Atossa’s communication programs.
“We are gratified to partner with Atossa on their important journey,” said Scott Gordon, Co-Founder and President of CORE IR. “The Company is focused on advancing breast cancer prevention and treatment by pioneering new therapies with innovative science. We look forward to helping the company increase its engagement with the broader investment community.”
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The Company's lead product candidate, (Z)-endoxifen, is a highly potent SERM/D designed for use across the breast cancer spectrum, including risk-reduction, and treatment in the neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.
Contacts:
Investors
CORE IR
ir@atossatherapeutics.com
(212) 655-0924
Media
Jules Abraham
CORE IR
pr@atossatherapeutics.com
(212) 655-0924
FAQ
What services will CORE IR provide to Atossa Therapeutics (NASDAQ:ATOS)?
Why did Atossa Therapeutics (NASDAQ:ATOS) appoint CORE IR?
What is Atossa Therapeutics' (NASDAQ:ATOS) main business focus?
Who announced the partnership between Atossa and CORE IR?
